Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period. METHODS: In this double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive placebo at baseline, at 12 months, and at 24 months; the patients were followed until 36 months. Primary end points were new vertebral fracture (in patients not taking concomitant osteoporosis medications) and hip fracture (in all patients). Secondary end points included bone mineral density, bone turnover markers, and safety outcomes. RESULTS: Treatment with zoledronic acid reduced the risk of morphometric vertebral fracture by 70% during a 3-year period, as compared with placebo (3.3% in the zoledronic-acid group vs. 10.9% in the placebo group; relative risk, 0.30; 95% confidence interval [CI], 0.24 to 0.38) and reduced the risk of hip fracture by 41% (1.4% in the zoledronic-acid group vs. 2.5% in the placebo group; hazard ratio, 0.59; 95% CI, 0.42 to 0.83). Nonvertebral fractures, clinical fractures, and clinical vertebral fractures were reduced by 25%, 33%, and 77%, respectively (P<0.001 for all comparisons). Zoledronic acid was also associated with a significant improvement in bone mineral density and bone metabolism markers. Adverse events, including change in renal function, were similar in the two study groups. However, serious atrial fibrillation occurred more frequently in the zoledronic acid group (in 50 vs. 20 patients, P<0.001). CONCLUSIONS: A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures. (ClinicalTrials.gov number, NCT00049829.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“There is abundant evidence that the elevated risk of fracture in patients with osteoporosis by BMD is reduced with pharmacotherapy [52, 57, 59–70].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationVertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Cummings, S. R. (1998) · JAMA · doi:10.1001/jama.280.24.2077 · Cited by 2,277
Self-citationOsteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Self-citationSystematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Woo, S.-B., Hellstein, J. W., & Kalmar, J. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00009 · Cited by 1,252
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Self-citationChesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., et al. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00490-3 · Cited by 1,122
Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis
Dr. Garnero, P., Sornay-Rendu, E., Chapuy, M.-C., & Delmas, P. D. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110307 · Cited by 1,001
Self-citationIntravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., Widmer, A., Devogelaer, J.-P., Kaufman, J.-M., Jaeger, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011807 · Cited by 877
Self-citationGarnero, P., Sornay-Rendu, E., Claustrat, B., & Delmas, P. D. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.8.1526 · Cited by 709
Self-citationSiris, E. S., Harris, S. T., Rosen, C. J., Barr, C. E., Arvesen, J. N., Abbott, T. A., & Silverman, S. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.8.1013 · Cited by 704
EFFECT OF RISEDRONATE ON THE RISK OF HIP FRACTURE IN ELDERLY WOMEN
Lung, R. M. C. C., Eusens, P. I. G., Aul, P., Iller, D. M., Ippel, H. A. Z., Ensen, W. I. G. B., Oux, C. H. R., Dami, S. I. A., Ogelman, I. G. F., Astell, R. I. E., et al. (2001) · Cited by 682
One Year of Alendronate after One Year of Parathyroid Hormone (1–84) for Osteoporosis
Black, D. M., Bilezikian, J. P., Ensrud, K. E., Greenspan, S. L., Palermo, L., Hue, T., Lang, T. F., McGowan, J. A., & Rosen, C. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050336 · Cited by 614
Self-citationCramer, J. A., Amonkar, M. M., Hebborn, A., & Altman, R. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x61875 · Cited by 390
Ruggiero, S. L., Gralow, J. R., Marx, R. E., Hoff, A. O., Schubert, M. M., Huryn, J. M., Toth, B., Damato, K., & Valero, V. (2006) · Journal of Oncology Practice · doi:10.1200/jop.2.1.7 · Cited by 355
Huybrechts, K. F., Ishak, K. J., & Caro, J. J. (2006) · Bone · doi:10.1016/j.bone.2005.10.022 · Cited by 346
Miller, P. D., Mcclung, M. R., Macovei, L., Stakkestad, J. A., Luckey, M., Bonvoisin, B., Reginster, J.-Y., Recker, R. R., Hughes, C., Lewiecki, E. M., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050313 · Cited by 333
Self-citationReginster, J.-Y., Adami, S., Lakatos, P., Greenwald, M., Stepan, J. J., Silverman, S. L., Christiansen, C., Rowell, L., Mairon, N., Bonvoisin, B., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.044958 · Cited by 326
Self-citation(BONE), F. T. O. I. O. V. F. T. I. N. A. A. E., Delmas, P. D., Recker, R. R., Chesnut, C. H., Skag, A., Stakkestad, J. A., Emkey, R., Gilbride, J., Schimmer, R. C., & Christiansen, C. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1602-9 · Cited by 279
Self-citationBlack, D. M., Palermo, L., Nevitt, M. C., Genant, H. K., Epstein, R., Valentin, R. S., & Cummings, S. R. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650100610 · Cited by 253
Self-citationRecker, R. R., Gallagher, R., & MacCosbe, P. E. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.7.856 · Cited by 250
Alendronate and Atrial Fibrillation
Cummings, S. R., Schwartz, A. V., & Black, D. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmc076132 · Cited by 230
Self-citationDefining Incident Vertebral Deformity: A Prospective Comparison of Several Approaches
Black, D. M., Palermo, L., Nevitt, M. C., Genant, H. K., Christensen, L., Cummings, S. R., & for the Study of Osteoporotic Fractures Research Group (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.1.90 · Cited by 186
Self-citationBonnick, S. L., Saag, K. G., Kiel, D. P., McClung, M. R., Hochberg, M. C., Burnett‐Bowie, S. M., Sebba, A. I., Kagan, R., Chen, E., Thompson, D. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2602 · Cited by 157
Persistence with weekly alendronate therapy among postmenopausal women
Lo, J. C.-M., Pressman, A. R., Omar, M. A., & Ettinger, B. B. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0085-2 · Cited by 151
Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy
Hoff, A. O., Toth, B. B., Altundağ, K., Guarneri, V., Adamus, A., Nooka, A. K., Sayegh, G., Johnson, M. M., Gagel, R. F., & Hortobágyi, G. N. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.8528 · Cited by 133
Bisphosphonates and Ocular Inflammation
Fraunfelder, F. W., & Fraunfelder, F. T. (2003) · New England Journal of Medicine · doi:10.1056/nejm200303203481225 · Cited by 125
Downey, T. W., Foltz-Boklage, S., Boccuzzi, S. J., Omar, M. A., & Kahler, K. H. (2006) · Southern Medical Journal · doi:10.1097/01.smj.0000221637.90495.66 · Cited by 85
Siris, E. S., Adachi, J. D., Lü, Y., Fuerst, T. P., Crans, G., Wong, M., Harper, K. D., & Genant, H. K. (2002) · Osteoporosis International · doi:10.1007/s001980200125 · Cited by 76
Sebba, A. I., Bonnick, S. L., Kagan, R., Thompson, D. E., Skalky, C. S., Chen, E., & de Papp, A. E. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x16768 · Cited by 62
Cited by
Clinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149
Self-citationDenosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Self-citationEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C., Rizzoli, R., Reginster, J.-Y., & on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) · Osteoporosis International · doi:10.1007/s00198-012-2074-y · Cited by 2,948
Osteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696
Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa074941 · Cited by 2,003
Self-citation
Metadata
- Authors
- Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., Mautalen, C., Mesenbrink, P., Hu, H., Caminis, J., Tong, K., Rosario-Jansen, T., Krasnow, J., Hue, T. F., Sellmeyer, D., Eriksen, E. F., & Cummings, S. R.
- Affiliations
- University of California, San Francisco (US)
- Lyon 1 Université (FR)
- University of Sheffield (GB)
- University of Auckland (NZ)
- KU Leuven (BE)
- University of Pittsburgh (US)
- Helen Hayes Hospital (US)
- Semmelweis University (HU)
- Chinese University of Hong Kong (HK)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-05-03
- Volume
- 356
- Issue
- 18
- Pages
- 1809-1822
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1993035292
- Cited by
- 2,986
- References
- 34
- Citations by year
- 2026: 90 · 2025: 120 · 2024: 107 · 2023: 96 · 2022: 114 · 2021: 140 · 2020: 127 · 2019: 124 · 2018: 127 · 2017: 121 · 2016: 150 · 2015: 154 · 2014: 154 · 2013: 194 · 2012: 174
- FWCI
- 258.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- ResearchSpace (University of Auckland) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000005)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- zoledronic acid, postmenopausal osteoporosis, bisphosphonates, fracture risk reduction, vertebral fractures, hip fracture, bone mineral density, bone turnover markers, atrial fibrillation, renal function
- MeSH terms
- Zoledronic Acid, Aged, Aged, 80 and over, Atrial Fibrillation, Diphosphonates, Double-Blind Method, Drug Administration Schedule, Female, Hip Fractures, Humans, Imidazoles, Infusions, Intravenous, Risk, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Incidence, Spinal Fractures, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.